A Biologic Definition of Burkitt's Lymphoma from Transcriptional and Genomic ProfilingMichael Hummel, Reiner Siebert, Stefan Bentink et al.|New England Journal of Medicine|2006Cited by 1k
Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registryAlessandro Pastore, Oliver Weigert, German Ott et al.|The Lancet Oncology|2015Cited by 613
Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemiaMonika Brüggemann, Michael Kneba, Thorsten Raff et al.|Blood|2005Cited by 537
Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)Roswitha Forstpointner, Wolfgang Hiddemann, Michael Unterhalt et al.|Blood|2006Cited by 465
Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell LymphomaConstantine S. Tam, Andrew W. Roberts, Mary Ann Anderson et al.|New England Journal of Medicine|2018Cited by 429